ArticleDiscover oncology2025
Histidine ammonia lyase expression characteristics in primary liver cancer: hepatocellular carcinoma and cholangiocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Reduced Histidine Metabolism Is Associated with Early Allograft Dysfunction Following Liver Transplantation.Metabolites · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundHistidine (His) ammonia Lyase (HAL) is a key rate-limiting enzyme that catalyzes the first reaction in the metabolism of histidine. Deficiencies in HAL lead to histidinemia, characterized by elevated levels of His in the blood and other body fluids. The level of HAL in these fluids is known to impact the sensitivity of cancer cells to certain chemotherapeutics by regulating His. However, the molecular role and impacts of HAL in the progression of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) are unknown at present. Thus, we investigated the expression of HAL in HCC and CCA tumors.
methodThe Cancer Genome Atlas (TCGA) database, quantitative real-time PCR (qRT-PCR), and immunoblot analysis were utilized to examine the expression of HAL in HCC and CCA patients.
resultsTCGA analysis revealed a significant downregulation of HAL mRNA expression in HCC and CCA tumor tissues compared with normal tissues (p < 0.0001). Our qRT-PCR and immunoblot analysis demonstrated a significant decrease in both HAL mRNA (HCC, n = 9, p < 0.05; CCA, n = 7, p < 0.05) and protein levels (HCC, 91.7%, 22/24; CCA, 92.9%, 13/14) in both HCC and CCA tumor tissues compared with adjacent non-tumor liver/ bile duct tissues across the majority of patient samples analyzed. The protein expression pattern aligns with the mRNA findings, indicating that HAL downregulation occurs at both transcriptional and protein levels.
conclusionOur data evinced the relevance and significance of HAL in the tumorigenesis of HCC and CCA. These findings suggest that HAL and its metabolic derivatives can be developed as a potential prognostic and diagnostic biomarker as well as therapeutics for HCC and CCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.